ENTITY
Yichang HEC Changjiang Pharma

Yichang HEC Changjiang Pharma (1558 HK)

83
Analysis
Health CareHong Kong
YiChang HEC ChangJiang Pharmaceutical Co Ltd develops a variety of drugs. The Company develops and sells drugs for anti-virus, metabolic diseases, cardiovascular, and more.
more
01 Sep 2024 09:30

China Healthcare Weekly (Sep.1)-Biotech Sell Asset,Pharmaceutical Distribution Company,HEC CJ Pharma

​Biotech's decision to sell pipeline will continue in sluggish market, leading to lower valuation. Pharmaceutical distribution companies face...

Logo
350 Views
Share
19 May 2024 07:05

Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid

Maybe this gets up. Maybe this is worth HK$19.30/share.  Too many maybes. If in, I'd vote this transaction down. If not in, I'd be looking elsewhere.

Logo
454 Views
Share
16 May 2024 08:55

HEC CJ Pharma (1558.HK)'s Merger Deal with Sunshine Lake Pharma - Almost No Investment Value

​Sunshine Lake Pharma plans to privatize and merge with CJ Pharma.However, with an outdated pipeline, the new entity's valuation performance will...

Logo
324 Views
Share
11 May 2024 23:48

HEC CJ Pharma (1558 HK): Pre-Conditional Share Exchange Offer from Largest Shareholder

There is scrip valuation uncertainty as the offeror is unlisted, and its valuation hinges on pipeline products. Nevertheless, the deal should get...

Logo
477 Views
Share
04 Jan 2024 09:30

HEC Pharma (1558 HK): Strong Performance to Continue as Flu Activity Is On Rise In China

HEC Pharma should benefit from the upsurge in respiratory illness in China. With a forward P/E of 4.8x and 14% YoY EPS growth expectation for 2024,...

Logo
650 Views
Share
x